Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioHarvest Sciences Inc. files Form 6-K current reports as a foreign issuer, with exhibits that document company announcements and material changes. These filings cover the company's Botanical Synthesis platform, its VINIA-branded nutraceutical products, CDMO activities for plant-based compounds, earnings-call announcements, and business updates.
The filing record also includes governance and capital-structure subjects such as board composition changes, executive leadership transitions, long-term incentive awards, stock options, restricted share units, and equity incentive plan activity. Together, the disclosures provide formal records of BioHarvest's operating focus, public-company governance, compensation structure, and recurring communications to the market.
BioHarvest Sciences Inc. reported that the Israel Innovation Authority approved a 4.33 million NIS (approximately USD $1.4 million) grant, structured as a non-dilutive, zero-interest loan. Repayment is contingent on predefined commercial milestones and is expected to come solely from revenues generated by the funded project, with no equity or equity-linked securities issued.
The funding supports a new research initiative that integrates advanced data science, machine learning, computer vision and high-throughput digital sensing into BioHarvest’s plant cell culture workflows, aiming to shift from trial-and-error to predictive, data-driven optimization and higher active metabolite yields. This is the second Israel Innovation Authority grant to BioHarvest this year, with the first focused on automating the manufacturing facility and the new grant targeting the early-stage R&D pipeline through predictive AI, together spanning discovery through to large-scale production.
BioHarvest Sciences Inc. reports that the Israel Innovation Authority has approved a 4.33 million NIS (approximately USD $1.4 million) non-dilutive grant to fund an AI-driven plant-cell synthesis research program. The funding will integrate data science, machine learning, computer vision and high-throughput digital sensing into its biological development workflows.
The project aims to replace trial-and-error plant cell culture with a predictive, data-focused platform that maximizes active metabolite yields for CDMO customers and partners. The grant is structured as a zero-interest loan, repayable only from future revenues generated by the funded project, and involves no equity or equity-linked issuance. It is the second Israel Innovation Authority grant this year, complementing a prior award focused on automating and scaling manufacturing operations.
BioHarvest Sciences Inc. filed a Form 6-K announcing it will present at the 2026 BIO International Convention in San Diego from June 22-25. The company’s session is scheduled for Wednesday, June 24 at 11:45 in Theater 3.
The presentation will highlight BioHarvest’s proprietary Botanical Synthesis™ platform, which produces plant-derived compounds with pharmaceutical-grade precision and commercial scalability. Management emphasizes recent capability expansion, increased partner engagement, and strategic initiatives aimed at collaborations with pharmaceutical and life science companies through its CDMO and nutraceutical businesses.
BioHarvest Sciences Inc. has called its annual general meeting for June 25, 2026 in Vancouver. Shareholders will vote to set the board size at seven directors, elect four nominees to staggered three- and one-year terms, and ratify Ziv Haft, Certified Public Accountants (Isr), BDO Member Firm, as auditor. They will also receive the audited financial statements for the year ended December 31, 2025.
The circular explains proxy and voting procedures for registered and beneficial owners and outlines executive and director compensation, including salary, option and RSU elements under the 2025 Equity Incentive Plan. As of the May 19, 2026 record date, 22,667,842 common shares were outstanding, with Vivien Rakib holding 3,041,674 shares, or 13.42%. The document also details the fully independent audit committee, its charter, and audit and related fees for 2024 and 2025.
BioHarvest Sciences reported first quarter 2026 revenue of $8.5 million, up 8% year over year, with gross margin improving to 59% from 58%. The business is managed through a CDMO services segment and a direct-to-consumer products segment.
Operating loss was $1.8 million, slightly wider than last year, and net loss was $2.6 million, or $0.11 per share. Adjusted EBITDA loss held roughly flat at $1.2 million, reflecting continued investment in growth rather than profitability.
On the CDMO side, BioHarvest advanced two Botanical Synthesis programs to Stage 2, with combined agreements valued at over $2 million, including a $1.2 million fragrance contract and a saffron program valued at over $1 million. On the D2C side, the VINIA brand reached 90,000 active users and its Blood Flow Hydration product generated $920,000 in cumulative revenue since launch, supported by a shift from TV to digital marketing. Cash and bank deposits totaled $20.2 million as of March 31, 2026.
BioHarvest Sciences Inc. reported Q1 2026 revenue of $8,507 thousand, up from $7,860 thousand a year earlier, driven mainly by its Products unit and strong CDMO services growth. Gross margin was about 59%, similar to last year, but the company still posted a net loss of $2,641 thousand, slightly larger than the prior period.
Cash and cash equivalents were $19,167 thousand as of March 31, 2026, giving positive working capital of $18,742 thousand. Management nonetheless discloses that recurring losses, ongoing investment needs and reliance on future financing raise substantial doubt about the company’s ability to continue as a going concern, even though they believe current resources support operations for at least the next 12 months.
BioHarvest Sciences Inc. has appointed Nedira Salzman-Frenkel as Vice President of Business Development for its contract development and manufacturing organization (CDMO) division. Her role focuses on sourcing and managing new contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic markets as the company grows this business.
The company states that Salzman-Frenkel will work closely with senior leadership to help deliver revenue targets and support the launch of a new facility next year. Her background includes senior business development roles in biotech and contract research, where she previously secured substantial CRO contracts and licensing arrangements.
BioHarvest Sciences Inc. reported that its CDMO division has successfully completed Stage 1 of a multi-stage saffron development agreement valued at $1.125 million. Stage 1 established a stable saffron cell bank with key bioactive compounds for potential nutraceutical and culinary uses.
Completion of Stage 1 triggers progression to Stage 2, which will use the company’s Botanical Synthesis™ platform in bioreactors to generate biomass for pre-commercial testing and product development. BioHarvest retains a 25% ownership interest in the saffron composition and is entitled to future manufacturing royalties on any saffron compounds produced using its platform.
BioHarvest Sciences Inc. reported that its CDMO division has signed a $1.2 million Stage 2 contract to develop a rare fragrance ingredient using its proprietary Botanical Synthesis platform. The source plant is described as one of the most valuable fragrance raw materials globally, with premium grades selling for tens of thousands of dollars per kilogram.
Stage 2 follows completion of Stage 1 in March 2026, when a stable cell bank containing rare molecules was created. Over the next six to nine months, BioHarvest aims to produce enough fragrance raw material for commercial trials. Under the agreement, the company retains 20% ownership of successfully developed compositions and is positioned as the manufacturing entity, supporting a long-term, royalty-driven economic model.
Management highlighted that this milestone advances BioHarvest toward potential production in the second half of 2027, aligned with a planned new production facility. The company links this opportunity to an estimated $23 billion premium fragrance segment within a $58.9 billion global scents and fragrances market.
BioHarvest Sciences Inc. has announced a strategic leadership transition focused on its direct-to-consumer and CDMO businesses. Co-founder and Executive Chairman Dr. Zaki Rakib has assumed the role of Chief Executive Officer, unifying leadership of R&D, manufacturing, and operations under a single structure.
Former CEO Ilan Sobel, who led the company from pre-revenue to approximately $35 million in revenue in fiscal year 2025, has stepped down from his executive role and joined the Board of Directors to concentrate on advancing the D2C business. The board highlighted Dr. Rakib’s more than 35 years of executive experience, his deep knowledge of BioHarvest’s technology platform, and his track record building high-growth companies, including scaling Terayon Communication Systems to $380 million in annual revenue and a $7 billion market capitalization as a Nasdaq-listed company.